文献速递湿疹皮炎与荨麻疹

甲氨蝶呤与硫唑嘌呤治疗重度特应性皮炎:随机对照试验的5年随访研究

Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial.
PubMed 文献 · Br J Dermatol · 2018-04-10

该研究为一项开放标签随访期临床试验,对43例最初入组的中重度特应性皮炎患者随访5年,每3个月评估一次,比较甲氨蝶呤(MTX)与硫唑嘌呤(AZA)的长期有效性、安全性和药物存活率。结论认为在中小样本实用性研究中,MTX与AZA作为中重度AD维持治疗至5年似乎有效且安全。

要点

  • 5年时MTX与AZA组SCORAD平均相对下降相似(53% vs 54%)。
  • MTX药物存活长于AZA,但5年后两组存活人数均少(MTX 5例,AZA 1例)。

核心结论

  • 基于该较小样本的实用性研究,MTX与AZA作为中重度AD维持治疗至5年似乎有效且安全。
  • 两组中仅少数患者维持原分配药物,部分因AD控制而停药。

研究设计与样本

  • 每3个月随访一次,MTX与AZA剂量可随日常临床实践增减。

主要发现

  • 5年时SCORAD指数平均相对下降:MTX组53%,AZA组54%(描述性分析)。
  • 药物存活分析显示MTX存活时间更长,但5年后两组存活均低(MTX n=5,AZA n=1)。

关键数值与推荐

  • 主要有效性指标为5年时SCORAD指数平均绝对和相对下降及IGA,与基线比较。
  • 安全性评估包括不良事件的类型、频率、严重程度及与治疗的相关性。
  • 药物存活率采用Kaplan-Meier曲线分析。

临床怎么用

  • MTX与AZA可作为中重度AD的长期维持治疗选择,但需注意5年内严重不良事件风险。
  • 部分患者可因AD控制而停药,长期用药需个体化评估。

局限性

  • 研究样本量相对较小(43例入组,27例完成随访),为实用性研究。
  • 开放标签设计,剂量可随临床实践调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic treatment is indicated for moderate-to-severe atopic dermatitis (AD) refractory to topical treatment. Long-term evidence, up to 5 years, of off-label prescribed methotrexate (MTX) and azathioprine (AZA) is lacking. OBJECTIVES: To investigate long-term effectiveness, safety and drug survival of MTX and AZA. METHODS: In an open-label follow-up phase of a clinical trial, patients were seen every 3 months for 5 years. MTX and AZA doses could be increased or decreased concurrent with daily clinical practice. Primary effectiveness outcomes were mean absolute and relative reduction in SCORing Atopic Dermatitis (SCORAD) index and Investigator's Global Assessment (IGA) after 5 years compared with baseline. To assess safety, the type, frequency, severity and relatedness to treatment of adverse events were investigated. Drug survival was analysed by Kaplan-Meier curves. RESULTS: Thirty-five of 43 originally included patients participated, of whom 27 completed the follow-up. At year 5, the mean relative reduction in SCORAD index was similar in the MTX and AZA groups: 53% and 54% using descriptive analysis. Twelve serious adverse events occurred in 5 years; for three there was a possible causal relationship. Drug survival demonstrated a longer survival for MTX, but survival in both groups was low after 5 years (MTXn = 5, AZAn = 1). CONCLUSIONS: Based on this relatively small pragmatic study, MTX and AZA seem to be effective and safe as maintenance treatments in moderate-to-severe AD up to 5 years. Few patients in both groups survive on their originally allocated drug although some discontinued because of controlled AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gerbens LAA, Hamann SAS, Brouwer MWD, et al. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018. PMID: 29237228. doi:10.1111/bjd.16240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。